ACTICOR BIOTECH provided an update on its clinical developments evaluating glenzocimab in the treatment of myocardial infarction. LIBERATE: A phase 2b study evaluating glenzocimab in the treatment of myocardial infarction. The Phase 2b, randomized, double-blind LIBERATE study will include more than 212 patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI).
The primary objective of the study is to evaluate the safety and effectiveness of glenzocimab 1000 mg compared to placebo, in reducing the size of the myocardial infarction 90 days after the event. This study is being carried out in partnership with the University of Birmingham (UK), with clinical experts from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust. The two main clinical research sites, the Queen Elizabeth Hospital in Birmingham and the Northern General Hospital in Sheffield, have been actively recruiting patients since January 2024.
To date, 27 patients have been enrolled and study results are expected in the fourth quarter of 2026. GLORIA: A phase 2 study evaluating glenzocimab in the treatment of myocardial infarction. A new randomized, double-blind Phase 2 GLORIA study is being prepared to evaluate glenzocimab in the treatment of myocardial infarction.
The study will include approximately 300 patients suffering from ST-segment elevation myocardial infarction during emergency admission to a cardiac intensive care unit. The main objective of the study is also to evaluate the effectiveness of glenzocimab in reducing myocardial infarction area on the 90th day after PCI (percutaneous coronary intervention), as well as its safety. The study plans to test several dose levels and optimize the mode of administration based on the time required for this emergency procedure.
The objective of launching this second study, which could be promoted by the Company, is to provide all the clinical and regulatory elements necessary for phase 3 registration from 2027, while evolving the method of administration of the product to facilitate the next stage of development and, later, adoption by clinicians. Patient recruitment could begin in the first quarter of 2025, subject to financing from the Company or the continuation of the project as envisaged in the receivership procedure.
